liver cirrhosis
Conditions
Interventions
Group 1:Interventional Devascularization Combination Carvedilol
Sponsors
Xijing Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Liver cirrhosis diagnosed by clinical examination, imaging or biopsy; 2. Patients with a previous history of variceal hemorrhage; 3. Gastric variceal confirmed by an endoscopic examination, including IGV1 or IGV2; 4. Aged 18 to 75 years; 5. adequate liver and kidney function, including Child-Turcotte-Pugh score < 12, MELD score <19, and serum creatinine less than 2 times the upper limit of normal.
Exclusion criteria
Exclusion criteria: 1. Active variceal bleeding; 2. Esophageal variceal, including GOV1 or GOV2 type, mainly esophageal varices; 3. Refractory ascites; 4. Patients with contraindication to treatment of TIPS, including congestive heart failure, NYHA III and IV, pulmonary arterial hypertension(>50mmHg), polycystic liver, intrahepatic duct dilatation, spontaneous bacterial peritonitis, hepatic encephalopathy; 5. Patients with contraindication to treatment of Carvedilol, including asthma, insulin-dependent diabetes, peripheral vascular diseases; 6. Child-Turcotte-Pugh score >=12, or MELD score >=19; 7. Budd-Chiari syndrome; 8. The main portal vein thrombosis is greater than 50%; 9. Malignancies; 10. An uncontrolled infection; 11. Previously treated with TIPS, splenectomy pericardia vascular disconnection, or surgical shunts; 12. HIV or HIV related illness; 13. Allergic to contrast agent; 14. Lactating or pregnant; 15. Non-compliant patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| No-rebleeding rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| mortality rate related to variceal hemorrhage;Overall survival;Incidence of hepatic encephalopathy;Changes in quality of life; | — |
Countries
China
Contacts
Public ContactTie Jun
Xijing HospitalXijing Hospital, The Air Force Medical University
Outcome results
None listed